Do analysts recommend TAOX or ACXP?

Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 2,052.78%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate ACXP or OPTH?

Acurx Pharmaceuticals currently has a consensus target price of $31.00, indicating a potential upside of 2,052.78%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Acurx Pharmaceuticals is more favorable than Optimi Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Optimi Health 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ACXP or OPTH more profitable?

Optimi Health's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -124.73% -87.48% Optimi Health N/A N/A N/A

Do analysts rate UPC or ACXP?

Acurx Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 2,052.78%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, UPC or ACXP?

Universe Pharmaceuticals has higher revenue and earnings than Acurx Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.86M 1.38 -$3.67M N/A N/A Acurx Pharmaceuticals N/A N/A -$7.97M -$2.69 N/A

Is UPC or ACXP more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Universe Pharmaceuticals N/A N/A N/A Acurx Pharmaceuticals N/A -124.73% -87.48%

Do analysts rate ACXP or BGM?

Acurx Pharmaceuticals currently has a consensus price target of $31.00, indicating a potential upside of 2,052.78%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acurx Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ACXP or BGM?

Acurx Pharmaceuticals has higher earnings, but lower revenue than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acurx Pharmaceuticals N/A N/A -$7.97M -$2.69 N/A BGM Group $37.92M 0.84 -$19.94M N/A N/A

Is ACXP or BGM more profitable?

BGM Group's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acurx Pharmaceuticals N/A -124.73% -87.48% BGM Group N/A N/A N/A

Acurx Pharmaceuticals (ACXP) Competitors

$1.44 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$1.45 +0.01 (+0.90%)

As of 04:58 AM Eastern

Compare

ACXP vs. TAOX, OPTH, UPC, AYTU, and BGM

Should you buy Acurx Pharmaceuticals stock or one of its competitors? Acurx Pharmaceuticals's main competitors and comparable companies include Synaptogenix (TAOX), Optimi Health (OPTH), Universe Pharmaceuticals (UPC), Aytu BioPharma (AYTU), and BGM Group (BGM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Acurx Pharmaceuticals compare to Synaptogenix?

Synaptogenix (NASDAQ:TAOX) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Acurx Pharmaceuticals has a consensus target price of $31.00, suggesting a potential upside of 2,052.78%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Acurx Pharmaceuticals has a net margin of 0.00% compared to Synaptogenix's net margin of -2,153.97%. Acurx Pharmaceuticals' return on equity of -124.73% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	-2,153.97%	-128.51%	-97.54%
Acurx Pharmaceuticals	N/A	-124.73%	-87.48%

Synaptogenix has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.03, indicating that its stock price is 303% less volatile than the broader market.

In the previous week, Synaptogenix and Synaptogenix both had 1 articles in the media. Synaptogenix's average media sentiment score of 1.87 equaled Acurx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Synaptogenix	Very Positive
Acurx Pharmaceuticals	Very Positive

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Acurx Pharmaceuticals has lower revenue, but higher earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$772.50K	37.68	-$28.74M	-$3.85	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$2.69	N/A

Summary

Acurx Pharmaceuticals beats Synaptogenix on 11 of the 13 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Optimi Health?

Acurx Pharmaceuticals (NASDAQ:ACXP) and Optimi Health (NASDAQ:OPTH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Optimi Health's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-124.73%	-87.48%
Optimi Health	N/A	N/A	N/A

In the previous week, Acurx Pharmaceuticals and Acurx Pharmaceuticals both had 1 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 1.87 equaled Optimi Health'saverage media sentiment score.

Company	Overall Sentiment
Acurx Pharmaceuticals	Very Positive
Optimi Health	Very Positive

Acurx Pharmaceuticals currently has a consensus target price of $31.00, indicating a potential upside of 2,052.78%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Acurx Pharmaceuticals is more favorable than Optimi Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Optimi Health	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Optimi Health has higher revenue and earnings than Acurx Pharmaceuticals. Optimi Health is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$2.69	N/A
Optimi Health	$175.67K	160.69	-$1.12M	-$0.76	N/A

11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 20.3% of Acurx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Acurx Pharmaceuticals beats Optimi Health on 6 of the 11 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Universe Pharmaceuticals?

Universe Pharmaceuticals (NASDAQ:UPC) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Universe Pharmaceuticals has higher revenue and earnings than Acurx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	1.38	-$3.67M	N/A	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$2.69	N/A

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Universe Pharmaceuticals' return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Acurx Pharmaceuticals	N/A	-124.73%	-87.48%

Universe Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.03, suggesting that its share price is 303% less volatile than the broader market.

In the previous week, Universe Pharmaceuticals had 2 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 3 mentions for Universe Pharmaceuticals and 1 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 1.87 beat Universe Pharmaceuticals' score of 0.30 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Universe Pharmaceuticals	Neutral
Acurx Pharmaceuticals	Very Positive

Acurx Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 2,052.78%. Given Acurx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Universe Pharmaceuticals beats Acurx Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Acurx Pharmaceuticals has lower revenue, but higher earnings than Aytu BioPharma. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.36	-$13.56M	-$4.58	N/A
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$2.69	N/A

Aytu BioPharma currently has a consensus price target of $10.75, indicating a potential upside of 377.78%. Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 2,052.78%. Given Acurx Pharmaceuticals' higher probable upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Acurx Pharmaceuticals has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Acurx Pharmaceuticals	N/A	-124.73%	-87.48%

In the previous week, Aytu BioPharma and Aytu BioPharma both had 1 articles in the media. Aytu BioPharma's average media sentiment score of 1.89 beat Acurx Pharmaceuticals' score of 1.87 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
Aytu BioPharma	Very Positive
Acurx Pharmaceuticals	Very Positive

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aytu BioPharma has a beta of 0.25, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Acurx Pharmaceuticals has a beta of -2.03, meaning that its stock price is 303% less volatile than the broader market.

Summary

Aytu BioPharma beats Acurx Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Acurx Pharmaceuticals compare to BGM Group?

Acurx Pharmaceuticals (NASDAQ:ACXP) and BGM Group (NASDAQ:BGM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Acurx Pharmaceuticals currently has a consensus price target of $31.00, indicating a potential upside of 2,052.78%. Given Acurx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Acurx Pharmaceuticals is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acurx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Acurx Pharmaceuticals has higher earnings, but lower revenue than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acurx Pharmaceuticals	N/A	N/A	-$7.97M	-$2.69	N/A
BGM Group	$37.92M	0.84	-$19.94M	N/A	N/A

Acurx Pharmaceuticals has a beta of -2.03, indicating that its share price is 303% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 20.3% of Acurx Pharmaceuticals shares are owned by company insiders. Comparatively, 58.7% of BGM Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Acurx Pharmaceuticals and Acurx Pharmaceuticals both had 1 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 1.87 equaled BGM Group'saverage media sentiment score.

Company	Overall Sentiment
Acurx Pharmaceuticals	Very Positive
BGM Group	Very Positive

BGM Group's return on equity of 0.00% beat Acurx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acurx Pharmaceuticals	N/A	-124.73%	-87.48%
BGM Group	N/A	N/A	N/A

Summary

Acurx Pharmaceuticals and BGM Group tied by winning 5 of the 10 factors compared between the two stocks.

Get Acurx Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACXP vs. The Competition

Export

Metric	Acurx Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.59M	$12.11B	$7.18B	$12.89B
Dividend Yield	N/A	2.62%	2.54%	11.27%
P/E Ratio	-0.54	787.65	273.17	25.45
Price / Sales	N/A	759.94	638.21	103.75
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	0.70	10.49	11.08	6.36
Net Income	-$7.97M	$2.83B	$3.48B	$349.79M
7 Day Performance	2.86%	0.58%	0.38%	-0.40%
1 Month Performance	N/A	5.69%	7.89%	4.24%
1 Year Performance	-68.83%	6.19%	24.71%	15.13%

Acurx Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACXP Acurx Pharmaceuticals	3.3716 of 5 stars	$1.44 flat	$31.00 +2,052.8%	-68.8%	$7.59M	N/A	N/A	3
TAOX Synaptogenix	0.4989 of 5 stars	$3.95 +1.0%	N/A	-33.2%	$29.26M	$300K	N/A	4	Positive News Gap Up
OPTH Optimi Health	1.5616 of 5 stars	$4.90 -1.6%	N/A	N/A	$28.51M	$290K	N/A	N/A	Positive News
UPC Universe Pharmaceuticals	0.6427 of 5 stars	$5.03 -6.2%	N/A	+38.0%	$26.93M	$17.86M	N/A	220	Analyst Upgrade
AYTU Aytu BioPharma	2.9825 of 5 stars	$2.35 +1.7%	$10.75 +357.4%	-4.3%	$24.79M	$66.38M	N/A	160	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACXP) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. TAOX, OPTH, UPC, AYTU, and BGM

How does Acurx Pharmaceuticals compare to Synaptogenix?

Summary

How does Acurx Pharmaceuticals compare to Optimi Health?

Summary

How does Acurx Pharmaceuticals compare to Universe Pharmaceuticals?

Summary

How does Acurx Pharmaceuticals compare to Aytu BioPharma?

Summary

How does Acurx Pharmaceuticals compare to BGM Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Acurx Pharmaceuticals (ACXP) Competitors

ACXP vs. TAOX, OPTH, UPC, AYTU, and BGM

How does Acurx Pharmaceuticals compare to Synaptogenix?

Do analysts recommend TAOX or ACXP?

Is TAOX or ACXP more profitable?

Which has more volatility and risk, TAOX or ACXP?

Does the media favor TAOX or ACXP?

Do insiders and institutionals have more ownership in TAOX or ACXP?

Which has better earnings and valuation, TAOX or ACXP?

Summary

How does Acurx Pharmaceuticals compare to Optimi Health?

Is ACXP or OPTH more profitable?

Does the media prefer ACXP or OPTH?

Do analysts rate ACXP or OPTH?

Which has higher earnings and valuation, ACXP or OPTH?

Do institutionals & insiders have more ownership in ACXP or OPTH?

Summary

How does Acurx Pharmaceuticals compare to Universe Pharmaceuticals?

Which has higher valuation and earnings, UPC or ACXP?

Do institutionals and insiders believe in UPC or ACXP?

Is UPC or ACXP more profitable?

Which has more volatility and risk, UPC or ACXP?

Does the media favor UPC or ACXP?

Do analysts rate UPC or ACXP?

Summary

How does Acurx Pharmaceuticals compare to Aytu BioPharma?

Which has better earnings and valuation, AYTU or ACXP?

Do analysts rate AYTU or ACXP?

Is AYTU or ACXP more profitable?

Does the media favor AYTU or ACXP?

Do institutionals & insiders have more ownership in AYTU or ACXP?

Which has more risk and volatility, AYTU or ACXP?

Summary

How does Acurx Pharmaceuticals compare to BGM Group?

Do analysts rate ACXP or BGM?

Which has preferable valuation & earnings, ACXP or BGM?

Which has more volatility & risk, ACXP or BGM?

Do insiders and institutionals have more ownership in ACXP or BGM?

Does the media refer more to ACXP or BGM?

Is ACXP or BGM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP vs. The Competition

Acurx Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools